24/7 Market News Snapshot 15 October, 2024 – Microbot Medical, Inc. Common Stock (NASDAQ:MBOT)

October 15, 2024

DENVER, Colo., 15 October, 2024 (247marketnews.com) – (NASDAQ:MBOT) are discussed in this article.
Microbot Medical, Inc. (MBOT) is witnessing a remarkable surge in pre-market trading, currently priced at $1.085—an increase of approximately 12.86% from its previous close of $0.961. The trading volume has reached 536.84K, reflecting a heightened interest among investors. This robust upward momentum indicates strong buying pressure, which suggests a positive sentiment in the market. Analysts suggest that a breakout above the $1.00 resistance level could further enhance investor confidence and propel the stock even higher. Traders are advised to monitor critical indicators such as volume spikes and moving averages to confirm the trend and identify potential entry points.

In parallel with its stock performance, Microbot Medical has marked a significant milestone by completing the enrollment and follow-up phase of its ACCESS-PVI human clinical trial. This development paves the way for the anticipated submission of the 510(k) application to the U.S. Food and Drug Administration (FDA) by the end of 2024. The trial focuses on assessing the safety and performance of the LIBERTY® Endovascular Robotic Surgical System, a groundbreaking technology designed to enhance efficiency and safety in endovascular procedures.

Harel Gadot, the Chairman, CEO, and President of Microbot Medical, expressed enthusiasm about the trial’s conclusion, highlighting the positive feedback from physicians and the urgency of preparations for the impending FDA submission. He stated, “This is a monumental moment and a significant achievement for Microbot Medical.” Furthermore, the company plans to present trial data at a leading medical conference in early 2025 and is committed to establishing a commercial infrastructure ahead of a potential FDA clearance in the second quarter of 2025. The innovations encapsulated in the LIBERTY® system reflect Microbot Medical’s dedication to enhancing clinical outcomes and broadening access to vital endovascular interventions.

Related news for (MBOT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.